Fuisz Pharma LLC Develops a New Generation of Oral Solid Dosage Form Shapes That Facilitate Swallowing and Esophageal Transit
MIAMI, April 6, 2011 /PRNewswire/ — Fuisz Pharma LLC announced today a new generation of solid dosage form designs that facilitate swallowing and esophageal transit.
Clinical studies demonstrate that these new designs and principles thereof speed esophageal transit by 80%, ease the swallowing experience, and reduce the incidence of esophageal transit failure, as compared with the conventional tablet designs currently used.
Joseph Fuisz, managing partner of Fuisz Pharma stated: “We stand at a crossroads where there is a keen understanding of the importance of compliance and the challenges to compliance posed by an aging population throughout the developed world. At the same time however, cost containment pressures — manifested primarily in reimbursement schemes — make it challenging for branded pharma to broadly adopt value added drug delivery technologies.”
“Our intention with this effort was to take existing tablet granulations and approach the question of form – as it relates to swallowability – from first principles. The results were quite astonishing in that we demonstrated the ability to make enormous improvements in the swallowability of conventionally manufactured dosage forms. Literally, we are able to take the existing granulation and stamp out a dramatically better performing product. This advance also applies to capsules. We are pursuing new dosage form classification for these next generation shapes in order to properly recognize their therapeutic value and to maximize the life cycle management benefit to our partners.”
Richard C. Fuisz, M.D., a founder of Fuisz Pharma, commented: “I have had the privilege of making substantial contributions to the development and commercialization of orally dissolving tablets and orally soluble films, both of which were granted new dosage form classification to distinguish them from the then existing dosage forms. Our new solid dosage form designs will represent my third oral dosage form and will ultimately prove to be the most important due to their extraordinary combination of high performance and ease of manufacture.”
The breakthrough is backed by clinical studies as well as in vitro studies and will change the way tablets and capsules look in the future. The work includes the end product as well as the press and mold designs to produce them. The inventions have been filed with the Unite States Patent and Trademark Office through multiple filings .
Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma. Fuisz Pharma has its headquarters in Miami. www.fuisz.com.
SOURCE Fuisz Pharma LLC